You can buy or sell MRTX and other stocks, options, ETFs, and crypto commission-free!
Mirati Therapeutics, Inc. Common Stock, also called Mirati Therapeutics, is a clinical-stage oncology company, which engages in developing a pipeline of oncology products to treat genetic, immunological and epigenetic drivers of cancer in subsets of cancer patients. Read More Its clinical pipeline consists of glesatinib, sitravatinib and mocetinostat. The company was founded on December 13, 1995 and is headquartered in San Diego, CA.
San Diego, California
52 Week High
52 Week Low
Stock Price, News, & Analysis for Mirati Therapeutics
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops targeted therapeutics to address the genetic, epigenetic, and immunological promoters of cancer. The company is involved in developing sitravatinib, an oral spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of solid tumor; and in Phase Ib clinical trial to treat non-small cell lung cancer (NCSLC) patients with CBL, chromosome 4q12, and RET genetic alterations, as well as mocetinostat, an orally administ...
Yahoo FinanceFeb 25
Analysis: Positioning to Benefit within Biogen, Mirati Therapeutics, PLDT, Zebra Technologies, Domino's Pizza, and Solar Capital — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Feb. 25, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Biogen Inc. (BIIB), Mirati Therapeutics, Inc. (MRTX), PLDT Inc. (PHI), Zebra Technologies Corporation (ZBRA), Domino's Pizza Inc (DPZ), and Solar Capital Ltd. (SLRC), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research. C...
Simply Wall StFeb 23
Mirati Therapeutics, Inc. (NASDAQ:MRTX) Insiders Have Been Selling
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! We’ve lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The flip side of that is that there are more than a few examples of insiders dumping stock prior to a period of weak performance. So before you buy or sell Mirati Therapeutics, Inc. (NASDAQ:MRTX), you may well want to know whether insiders have been buying or selling. What Is Insid...
Expected May 6, After Hours